GE HealthCare Technologies Key Executives
This section highlights GE HealthCare Technologies's key executives, including their titles and compensation details.
Find Contacts at GE HealthCare Technologies
(Showing 0 of )
GE HealthCare Technologies Earnings
This section highlights GE HealthCare Technologies's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-13 | $1.26 | $1.45 |
| Read Transcript | Q3 | 2024 | 2024-10-30 | $1.05 | $1.14 |
| Read Transcript | Q2 | 2024 | 2024-07-31 | $0.98 | $1.00 |
| Read Transcript | Q1 | 2024 | 2024-04-30 | $0.91 | $0.90 |
| Read Transcript | Q4 | 2023 | 2024-02-06 | $1.07 | $1.18 |
| Read Transcript | Q3 | 2023 | 2023-11-03 | N/A | N/A |
| Read Transcript | Q2 | 2023 | 2023-07-25 | $0.87 | $0.92 |
| Read Transcript | Q1 | 2023 | 2023-04-25 | $0.79 | $0.85 |
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
$82.46
Stock Price
$37.71B
Market Cap
-
Employees
Chicago, IL
Location
Financial Statements
Access annual & quarterly financial statements for GE HealthCare Technologies, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $19.67B | $19.55B | $18.34B | $17.59B | $17.16B |
| Cost of Revenue | $11.47B | $11.63B | $11.16B | $10.41B | $10.40B |
| Gross Profit | $8.21B | $7.92B | $7.18B | $7.17B | $6.77B |
| Gross Profit Ratio | 41.71% | 40.50% | 39.14% | 40.80% | 39.43% |
| Research and Development Expenses | $1.31B | $1.21B | $1.03B | $816.00M | $810.00M |
| General and Administrative Expenses | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $4.27B | $4.28B | $3.63B | $3.56B | $3.24B |
| Other Expenses | $- | $- | $67.00M | $59.00M | $- |
| Operating Expenses | $5.58B | $5.49B | $4.66B | $4.38B | $4.05B |
| Cost and Expenses | $17.05B | $17.12B | $15.82B | $14.79B | $14.44B |
| Interest Income | $- | $26.00M | $86.00M | $34.00M | $49.00M |
| Interest Expense | $505.00M | $542.00M | $77.00M | $40.00M | $66.00M |
| Depreciation and Amortization | $580.00M | $610.00M | $633.00M | $625.00M | $630.00M |
| EBITDA | $3.67B | $3.51B | $3.17B | $3.54B | $3.41B |
| EBITDA Ratio | 18.64% | 17.97% | 17.57% | 20.13% | 19.84% |
| Operating Income | $2.62B | $2.44B | $2.52B | $2.79B | $2.72B |
| Operating Income Ratio | 13.34% | 12.45% | 13.75% | 15.89% | 15.85% |
| Total Other Income Expenses Net | $-44.00M | $-74.00M | $-10.00M | $80.00M | $-10.00M |
| Income Before Tax | $2.58B | $2.36B | $2.51B | $2.88B | $2.71B |
| Income Before Tax Ratio | 13.12% | 12.08% | 13.70% | 16.35% | 15.79% |
| Income Tax Expense | $531.00M | $743.00M | $563.00M | $600.00M | $652.00M |
| Net Income | $1.99B | $1.57B | $1.92B | $2.25B | $2.06B |
| Net Income Ratio | 10.13% | 8.02% | 10.45% | 12.78% | 11.99% |
| EPS | $4.37 | $3.04 | $4.22 | $4.90 | $4.53 |
| EPS Diluted | $4.34 | $3.02 | $4.22 | $4.90 | $4.53 |
| Weighted Average Shares Outstanding | 456.00M | 455.00M | 453.93M | 454.71M | 454.71M |
| Weighted Average Shares Outstanding Diluted | 459.00M | 458.00M | 453.93M | 454.71M | 454.71M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.32B | $4.86B | $4.84B | $4.65B | $5.21B | $4.82B | $4.82B | $4.71B | $4.94B | $4.58B | $4.48B | $4.34B | $4.59B | $4.30B | $4.35B | $4.35B |
| Cost of Revenue | $3.04B | $2.84B | $2.84B | $2.75B | $3.05B | $2.89B | $2.88B | $2.82B | $3.01B | $2.80B | $2.69B | $2.67B | $2.73B | $2.54B | $2.57B | $2.57B |
| Gross Profit | $2.27B | $2.02B | $2.00B | $1.90B | $2.16B | $1.94B | $1.94B | $1.89B | $1.93B | $1.77B | $1.80B | $1.68B | $1.86B | $1.77B | $1.77B | $1.77B |
| Gross Profit Ratio | 42.77% | 41.60% | 41.20% | 40.90% | 41.40% | 40.10% | 40.30% | 40.20% | 39.10% | 38.70% | 40.10% | 38.60% | 40.60% | 41.00% | 40.80% | 40.80% |
| Research and Development Expenses | $344.00M | $316.00M | $327.00M | $324.00M | $315.00M | $322.00M | $298.00M | $270.00M | $271.00M | $260.00M | $257.00M | $238.00M | $225.00M | $200.00M | $195.50M | $195.50M |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $1.13B | $1.03B | $1.00B | $1.04B | $1.15B | $996.00M | $1.07B | $1.06B | $884.00M | $908.00M | $908.00M | $931.00M | $910.00M | $914.00M | $869.50M | $869.50M |
| Other Expenses | $- | $- | $99.00M | $108.00M | $42.00M | $157.00M | $137.00M | $106.00M | $-18.00M | $12.00M | $24.00M | $27.00M | $18.00M | $- | $- | $- |
| Operating Expenses | $1.47B | $1.35B | $1.33B | $1.36B | $1.47B | $1.32B | $1.37B | $1.33B | $1.16B | $1.17B | $1.17B | $1.17B | $1.14B | $1.08B | $1.05B | $1.05B |
| Cost and Expenses | $4.52B | $4.19B | $4.17B | $4.11B | $4.52B | $4.21B | $4.25B | $4.15B | $4.16B | $3.97B | $3.85B | $3.83B | $3.86B | $3.62B | $3.62B | $3.62B |
| Interest Income | $- | $5.00M | $- | $- | $7.00M | $6.00M | $137.00M | $13.00M | $- | $2.00M | $- | $- | $6.00M | $10.00M | $2.00M | $2.00M |
| Interest Expense | $111.00M | $130.00M | $131.00M | $138.00M | $131.00M | $138.00M | $137.00M | $136.00M | $59.00M | $- | $22.00M | $6.00M | $6.00M | $- | $- | $- |
| Depreciation and Amortization | $140.00M | $143.00M | $150.00M | $148.00M | $144.00M | $153.00M | $156.00M | $157.00M | $157.00M | $160.00M | $157.00M | $159.00M | $154.00M | $155.00M | $158.00M | $158.00M |
| EBITDA | $1.08B | $933.00M | $862.00M | $792.00M | $991.00M | $927.00M | $848.00M | $839.00M | $938.00M | $767.00M | $790.00M | $670.00M | $915.00M | $808.00M | $866.00M | $866.00M |
| EBITDA Ratio | 20.40% | 19.19% | 16.82% | 17.16% | 16.98% | 19.22% | 14.68% | 17.82% | 15.74% | 17.05% | 18.24% | 16.07% | 19.94% | 18.77% | 19.93% | 19.93% |
| Operating Income | $801.00M | $676.00M | $664.00M | $540.00M | $689.00M | $617.00M | $570.00M | $559.00M | $620.00M | $605.00M | $631.00M | $509.00M | $727.00M | $653.00M | $708.00M | $708.00M |
| Operating Income Ratio | 15.06% | 13.90% | 13.72% | 11.61% | 13.23% | 12.80% | 11.83% | 11.88% | 12.56% | 13.22% | 14.07% | 11.72% | 15.84% | 15.17% | 16.29% | 16.29% |
| Total Other Income Expenses Net | $33.00M | $-18.00M | $-86.00M | $-28.00M | $-80.00M | $19.00M | $- | $-13.00M | $-59.00M | $17.00M | $8.00M | $24.00M | $28.00M | $24.00M | $14.00M | $14.00M |
| Income Before Tax | $834.00M | $658.00M | $578.00M | $512.00M | $609.00M | $636.00M | $570.00M | $546.00M | $718.00M | $622.00M | $639.00M | $533.00M | $755.00M | $677.00M | $722.00M | $722.00M |
| Income Before Tax Ratio | 15.68% | 13.53% | 11.94% | 11.01% | 11.70% | 13.19% | 11.83% | 11.60% | 14.54% | 13.59% | 14.25% | 12.27% | 16.45% | 15.73% | 16.61% | 16.61% |
| Income Tax Expense | $96.00M | $168.00M | $143.00M | $124.00M | $193.00M | $250.00M | $137.00M | $163.00M | $151.00M | $128.00M | $153.00M | $131.00M | $179.00M | $160.00M | $130.50M | $130.50M |
| Net Income | $720.00M | $471.00M | $428.00M | $374.00M | $403.00M | $375.00M | $418.00M | $372.00M | $554.00M | $488.00M | $485.00M | $389.00M | $564.00M | $504.00M | $581.00M | $581.00M |
| Net Income Ratio | 13.54% | 9.69% | 8.84% | 8.04% | 7.74% | 7.78% | 8.68% | 7.90% | 11.22% | 10.66% | 10.82% | 8.96% | 12.29% | 11.71% | 13.37% | 13.37% |
| EPS | $1.58 | $1.03 | $0.94 | $0.82 | $0.89 | $0.82 | $0.92 | $0.42 | $1.22 | $1.07 | $1.07 | $0.86 | $1.27 | $1.11 | $1.28 | $1.28 |
| EPS Diluted | $1.57 | $1.02 | $0.93 | $0.81 | $0.88 | $0.82 | $0.91 | $0.41 | $1.22 | $1.07 | $1.07 | $0.86 | $1.27 | $1.11 | $1.28 | $1.28 |
| Weighted Average Shares Outstanding | 457.00M | 457.00M | 457.00M | 456.00M | 455.00M | 455.00M | 455.00M | 454.00M | 453.93M | 454.00M | 454.00M | 453.93M | 454.71M | 454.71M | 454.71M | 454.71M |
| Weighted Average Shares Outstanding Diluted | 459.00M | 459.00M | 459.00M | 459.00M | 458.00M | 458.00M | 458.00M | 457.00M | 453.93M | 454.71M | 454.71M | 454.71M | 454.71M | 454.71M | 454.71M | 454.71M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $2.87B | $2.49B | $1.45B | $554.00M | $994.00M |
| Short Term Investments | $15.00M | $- | $- | $- | $- |
| Cash and Short Term Investments | $2.89B | $2.49B | $1.45B | $554.00M | $994.00M |
| Net Receivables | $3.56B | $4.25B | $3.99B | $3.79B | $2.66B |
| Inventory | $1.94B | $1.96B | $2.15B | $1.95B | $1.59B |
| Other Current Assets | $- | $702.00M | $1.12B | $709.00M | $651.00M |
| Total Current Assets | $8.39B | $9.41B | $8.32B | $7.00B | $5.90B |
| Property Plant Equipment Net | $2.55B | $2.50B | $2.31B | $2.23B | $2.20B |
| Goodwill | $13.14B | $12.94B | $12.81B | $12.89B | $11.87B |
| Intangible Assets | $1.08B | $1.25B | $1.52B | $1.85B | $1.60B |
| Goodwill and Intangible Assets | $14.21B | $14.19B | $14.33B | $14.74B | $13.47B |
| Long Term Investments | $373.00M | $357.00M | $322.00M | $341.00M | $344.00M |
| Tax Assets | $4.47B | $4.47B | $1.55B | $1.71B | $1.94B |
| Other Non-Current Assets | $1.58B | $1.52B | $702.00M | $286.00M | $375.00M |
| Total Non-Current Assets | $23.19B | $23.04B | $19.22B | $19.31B | $18.33B |
| Other Assets | $1.51B | $- | $- | $- | $- |
| Total Assets | $33.09B | $32.45B | $27.54B | $26.31B | $24.23B |
| Account Payables | $3.02B | $2.95B | $2.94B | $2.54B | $2.16B |
| Short Term Debt | $1.62B | $1.12B | $119.00M | $110.00M | $260.00M |
| Tax Payables | $279.00M | $- | $- | $- | $- |
| Deferred Revenue | $- | $1.92B | $1.90B | $1.86B | $1.81B |
| Other Current Liabilities | $4.63B | $3.00B | $2.23B | $2.25B | $2.29B |
| Total Current Liabilities | $9.55B | $8.98B | $7.19B | $6.76B | $6.52B |
| Long Term Debt | $310.00M | $8.75B | $8.52B | $327.00M | $336.00M |
| Deferred Revenue Non-Current | $- | $705.00M | $630.00M | $632.00M | $569.00M |
| Deferred Tax Liabilities Non-Current | $56.00M | $68.00M | $370.00M | $385.00M | $459.00M |
| Other Non-Current Liabilities | $14.52B | $6.64B | $1.24B | $1.31B | $1.59B |
| Total Non-Current Liabilities | $14.88B | $16.16B | $10.99B | $2.87B | $2.95B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $24.44B | $25.14B | $18.18B | $9.63B | $9.48B |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $5.00M | $5.00M | $11.23B | $17.69B | $15.57B |
| Retained Earnings | $3.26B | $1.33B | $- | $- | $- |
| Accumulated Other Comprehensive Income Loss | $-1.38B | $-691.00M | $-1.88B | $-1.04B | $-839.00M |
| Other Total Stockholders Equity | $6.56B | $6.49B | $- | $- | $- |
| Total Stockholders Equity | $8.45B | $7.13B | $9.36B | $16.66B | $14.73B |
| Total Equity | $8.63B | $7.31B | $9.36B | $16.68B | $14.75B |
| Total Liabilities and Stockholders Equity | $33.09B | $32.45B | $27.54B | $26.31B | $24.23B |
| Minority Interest | $188.00M | $177.00M | $5.00M | $21.00M | $24.00M |
| Total Liabilities and Total Equity | $33.09B | $32.45B | $27.54B | $26.31B | $24.23B |
| Total Investments | $373.00M | $357.00M | $322.00M | $341.00M | $344.00M |
| Total Debt | $1.50B | $9.86B | $8.25B | $437.00M | $468.00M |
| Net Debt | $-1.39B | $7.37B | $6.80B | $-117.00M | $-526.00M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | March 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $2.87B | $3.55B | $2.01B | $2.55B | $2.49B | $2.42B | $1.94B | $2.32B | $1.45B | $498.00M | $523.00M | $-554.00M | $554.00M | $-1.01B |
| Short Term Investments | $15.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.11B | $- | $2.01B |
| Cash and Short Term Investments | $2.89B | $3.55B | $2.01B | $2.55B | $2.49B | $2.42B | $1.94B | $2.32B | $1.45B | $498.00M | $523.00M | $554.00M | $554.00M | $1.01B |
| Net Receivables | $3.56B | $4.20B | $4.06B | $4.09B | $4.32B | $4.15B | $4.14B | $4.10B | $3.99B | $3.65B | $3.43B | $- | $3.79B | $- |
| Inventory | $1.94B | $2.12B | $2.02B | $1.99B | $1.96B | $2.13B | $2.26B | $2.26B | $2.15B | $2.20B | $2.24B | $- | $1.95B | $- |
| Other Current Assets | $- | $760.00M | $1.10B | $1.21B | $1.11B | $775.00M | $897.00M | $927.00M | $1.12B | $935.00M | $1.22B | $- | $709.00M | $- |
| Total Current Assets | $8.39B | $10.64B | $8.44B | $9.37B | $9.41B | $9.47B | $9.24B | $9.60B | $8.32B | $7.28B | $7.41B | $554.00M | $7.00B | $1.01B |
| Property Plant Equipment Net | $2.55B | $2.54B | $2.46B | $2.44B | $2.50B | $2.35B | $2.36B | $2.33B | $2.31B | $2.08B | $2.16B | $- | $2.23B | $- |
| Goodwill | $13.14B | $13.14B | $13.12B | $12.93B | $12.94B | $12.91B | $12.93B | $12.92B | $12.81B | $12.77B | $12.82B | $- | $12.89B | $- |
| Intangible Assets | $1.08B | $1.13B | $1.20B | $1.17B | $1.25B | $1.33B | $1.42B | $1.49B | $1.52B | $1.60B | $1.70B | $- | $1.85B | $- |
| Goodwill and Intangible Assets | $14.21B | $14.27B | $14.31B | $14.10B | $14.19B | $14.25B | $14.35B | $14.42B | $14.33B | $14.37B | $14.52B | $- | $14.74B | $- |
| Long Term Investments | $373.00M | $361.00M | $749.00M | $346.00M | $357.00M | $402.00M | $407.00M | $392.00M | $322.00M | $-1.31B | $- | $- | $341.00M | $- |
| Tax Assets | $4.47B | $4.31B | $4.37B | $4.41B | $4.47B | $4.28B | $4.35B | $4.34B | $1.55B | $1.31B | $- | $- | $1.71B | $- |
| Other Non-Current Assets | $1.58B | $1.74B | $1.53B | $1.53B | $1.52B | $1.63B | $1.61B | $1.56B | $702.00M | $2.34B | $2.38B | $-554.00M | $286.00M | $-1.01B |
| Total Non-Current Assets | $23.19B | $23.22B | $23.41B | $22.84B | $23.04B | $22.91B | $23.07B | $23.03B | $19.22B | $18.79B | $19.06B | $-554.00M | $19.31B | $-1.01B |
| Other Assets | $1.51B | $1.00M | $- | $-2.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $33.09B | $33.85B | $31.85B | $32.21B | $32.45B | $32.38B | $32.31B | $32.64B | $27.54B | $26.07B | $26.46B | $- | $26.31B | $- |
| Account Payables | $3.02B | $2.91B | $2.82B | $2.93B | $2.95B | $2.77B | $2.83B | $2.98B | $2.94B | $2.69B | $2.70B | $- | $2.54B | $- |
| Short Term Debt | $1.62B | $1.12B | $1.12B | $1.12B | $1.12B | $7.00M | $5.00M | $5.00M | $119.00M | $12.00M | $6.00M | $- | $110.00M | $- |
| Tax Payables | $279.00M | $160.00M | $200.00M | $266.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $1.92B | $1.88B | $1.88B | $1.92B | $1.93B | $2.00B | $2.03B | $1.90B | $1.76B | $- | $- | $1.86B | $- |
| Other Current Liabilities | $4.63B | $2.56B | $2.30B | $2.67B | $3.00B | $2.86B | $2.74B | $3.22B | $2.23B | $3.94B | $3.98B | $- | $2.25B | $- |
| Total Current Liabilities | $9.55B | $8.67B | $8.32B | $8.86B | $8.98B | $7.57B | $7.58B | $8.24B | $7.19B | $6.63B | $6.69B | $- | $6.76B | $- |
| Long Term Debt | $310.00M | $9.61B | $8.54B | $8.55B | $8.75B | $10.62B | $10.23B | $10.23B | $8.52B | $31.00M | $367.00M | $- | $327.00M | $- |
| Deferred Revenue Non-Current | $- | $704.00M | $685.00M | $687.00M | $705.00M | $5.53B | $5.17B | $650.00M | $630.00M | $368.00M | $- | $- | $632.00M | $- |
| Deferred Tax Liabilities Non-Current | $56.00M | $59.00M | $55.00M | $68.00M | $68.00M | $62.00M | $81.00M | $64.00M | $370.00M | $368.00M | $- | $- | $385.00M | $- |
| Other Non-Current Liabilities | $14.52B | $6.30B | $6.26B | $6.44B | $6.64B | $6.83B | $7.09B | $7.21B | $1.24B | $1.79B | $2.13B | $- | $1.31B | $- |
| Total Non-Current Liabilities | $14.88B | $16.67B | $15.54B | $15.75B | $16.16B | $17.68B | $17.41B | $17.70B | $10.99B | $2.55B | $2.50B | $- | $2.87B | $- |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $24.44B | $25.34B | $23.86B | $24.61B | $25.14B | $25.24B | $24.99B | $25.94B | $18.18B | $9.19B | $9.19B | $- | $9.63B | $- |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $5.00M | $5.00M | $5.00M | $5.00M | $5.00M | $5.00M | $5.00M | $5.00M | $11.23B | $18.80B | $18.68B | $- | $17.69B | $- |
| Retained Earnings | $3.26B | $2.56B | $2.10B | $1.69B | $1.33B | $937.00M | $576.00M | $185.00M | $- | $- | $- | $- | $- | $- |
| Accumulated Other Comprehensive Income Loss | $-1.38B | $-771.00M | $-845.00M | $-787.00M | $-691.00M | $-280.00M | $70.00M | $75.00M | $-1.88B | $-1.94B | $-1.65B | $16.66B | $-1.04B | $14.73B |
| Other Total Stockholders Equity | $6.56B | $6.53B | $6.54B | $6.50B | $6.49B | $6.47B | $6.45B | $6.42B | $- | $- | $- | $241.00M | $- | $247.00M |
| Total Stockholders Equity | $8.45B | $8.32B | $7.80B | $7.41B | $7.13B | $7.13B | $7.10B | $6.69B | $9.36B | $16.86B | $17.03B | $16.90B | $16.66B | $14.97B |
| Total Equity | $8.63B | $8.51B | $7.99B | $7.60B | $7.31B | $7.14B | $7.32B | $6.70B | $9.36B | $16.88B | $17.27B | $16.90B | $16.68B | $14.97B |
| Total Liabilities and Stockholders Equity | $33.09B | $33.85B | $31.85B | $32.21B | $32.45B | $32.38B | $32.31B | $32.64B | $27.54B | $26.07B | $26.46B | $16.90B | $26.31B | $14.97B |
| Minority Interest | $188.00M | $195.00M | $193.00M | $191.00M | $177.00M | $11.00M | $221.00M | $6.00M | $5.00M | $19.00M | $243.00M | $- | $21.00M | $- |
| Total Liabilities and Total Equity | $33.09B | $33.85B | $31.85B | $32.21B | $32.45B | $32.38B | $32.31B | $32.64B | $27.54B | $26.07B | $26.46B | $16.90B | $26.31B | $14.97B |
| Total Investments | $373.00M | $361.00M | $749.00M | $346.00M | $357.00M | $402.00M | $407.00M | $392.00M | $322.00M | $-1.31B | $- | $1.11B | $341.00M | $2.01B |
| Total Debt | $1.50B | $10.73B | $9.66B | $9.67B | $9.86B | $10.26B | $10.24B | $10.24B | $8.25B | $43.00M | $373.00M | $- | $437.00M | $- |
| Net Debt | $-1.39B | $7.18B | $7.65B | $7.12B | $7.37B | $7.84B | $8.30B | $7.92B | $6.80B | $-455.00M | $-150.00M | $554.00M | $-117.00M | $1.01B |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $2.05B | $1.57B | $1.95B | $2.27B | $2.06B |
| Depreciation and Amortization | $580.00M | $610.00M | $633.00M | $625.00M | $630.00M |
| Deferred Income Tax | $531.00M | $743.00M | $563.00M | $600.00M | $652.00M |
| Stock Based Compensation | $125.00M | $114.00M | $67.00M | $76.00M | $- |
| Change in Working Capital | $-59.00M | $-131.00M | $-256.00M | $-1.37B | $-52.00M |
| Accounts Receivables | $-178.00M | $-185.00M | $-231.00M | $-1.34B | $-221.00M |
| Inventory | $-81.00M | $111.00M | $-402.00M | $-435.00M | $100.00M |
| Accounts Payables | $126.00M | $-13.00M | $481.00M | $263.00M | $-113.00M |
| Other Working Capital | $74.00M | $-44.00M | $-104.00M | $138.00M | $182.00M |
| Other Non Cash Items | $-1.28B | $-803.00M | $-843.00M | $-599.00M | $-670.00M |
| Net Cash Provided by Operating Activities | $1.95B | $2.10B | $2.11B | $1.61B | $1.69B |
| Investments in Property Plant and Equipment | $-401.00M | $-387.00M | $-310.00M | $-248.00M | $-259.00M |
| Acquisitions Net | $- | $-147.00M | $4.00M | $-1.48B | $-78.00M |
| Purchases of Investments | $-40.00M | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $-473.00M | $-24.00M | $-92.00M | $-32.00M | $20.32B |
| Net Cash Used for Investing Activities | $-914.00M | $-558.00M | $-398.00M | $-1.76B | $19.99B |
| Debt Repayment | $-423.00M | $1.14B | $8.20B | $-12.00M | $-16.00M |
| Common Stock Issued | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $-55.00M | $-41.00M | $- | $- | $- |
| Other Financing Activities | $-95.00M | $-1.58B | $-9.03B | $-251.00M | $-21.53B |
| Net Cash Used Provided by Financing Activities | $-573.00M | $-478.00M | $-822.00M | $-263.00M | $-21.54B |
| Effect of Forex Changes on Cash | $- | $-10.00M | $-3.00M | $-34.00M | $14.00M |
| Net Change in Cash | $387.00M | $1.05B | $890.00M | $-451.00M | $143.00M |
| Cash at End of Period | $2.89B | $2.51B | $1.45B | $561.00M | $1.01B |
| Cash at Beginning of Period | $2.51B | $1.45B | $561.00M | $1.01B | $869.00M |
| Operating Cash Flow | $1.95B | $2.10B | $2.11B | $1.61B | $1.69B |
| Capital Expenditure | $-401.00M | $-387.00M | $-310.00M | $-248.00M | $-259.00M |
| Free Cash Flow | $1.55B | $1.71B | $1.80B | $1.36B | $1.43B |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $738.00M | $489.00M | $428.00M | $388.00M | $416.00M | $386.00M | $433.00M | $383.00M | $567.00M | $494.00M | $486.00M | $402.00M | $576.00M | $514.00M | $584.50M | $584.50M |
| Depreciation and Amortization | $140.00M | $143.00M | $150.00M | $148.00M | $144.00M | $153.00M | $156.00M | $157.00M | $157.00M | $160.00M | $157.00M | $159.00M | $154.00M | $155.00M | $158.00M | $158.00M |
| Deferred Income Tax | $96.00M | $168.00M | $143.00M | $124.00M | $193.00M | $250.00M | $137.00M | $163.00M | $151.00M | $128.00M | $153.00M | $131.00M | $179.00M | $- | $- | $- |
| Stock Based Compensation | $33.00M | $22.00M | $36.00M | $34.00M | $33.00M | $29.00M | $28.00M | $24.00M | $9.00M | $19.00M | $20.00M | $19.00M | $- | $- | $- | $- |
| Change in Working Capital | $215.00M | $83.00M | $-501.00M | $154.00M | $213.00M | $-146.00M | $-283.00M | $85.00M | $166.00M | $-35.00M | $-377.00M | $-10.00M | $-889.00M | $-168.00M | $-382.50M | $-382.50M |
| Accounts Receivables | $-224.00M | $-69.00M | $-37.00M | $155.00M | $-103.00M | $-50.00M | $-10.00M | $-22.00M | $-124.00M | $54.00M | $-22.00M | $-139.00M | $-766.00M | $-35.00M | $-266.00M | $-266.00M |
| Inventory | $76.00M | $-41.00M | $-57.00M | $-59.00M | $196.00M | $87.00M | $-50.00M | $-122.00M | $140.00M | $-95.00M | $-203.00M | $-244.00M | $-112.00M | $-171.00M | $-76.00M | $-76.00M |
| Accounts Payables | $123.00M | $44.00M | $-122.00M | $81.00M | $80.00M | $-53.00M | $-127.00M | $87.00M | $112.00M | $87.00M | $-37.00M | $319.00M | $-119.00M | $- | $- | $- |
| Other Working Capital | $240.00M | $149.00M | $-285.00M | $-18.00M | $40.00M | $-130.00M | $-96.00M | $142.00M | $38.00M | $-81.00M | $-115.00M | $54.00M | $108.00M | $38.00M | $-40.50M | $-40.50M |
| Other Non Cash Items | $-309.00M | $-167.00M | $177.00M | $-166.00M | $51.00M | $-22.00M | $-538.00M | $-344.00M | $450.00M | $-535.00M | $-458.00M | $-233.00M | $-31.00M | $77.00M | $160.00M | $160.00M |
| Net Cash Provided by Operating Activities | $913.00M | $738.00M | $-119.00M | $419.00M | $1.05B | $650.00M | $-67.00M | $468.00M | $1.04B | $622.00M | $-19.00M | $468.00M | $-11.00M | $578.00M | $520.00M | $520.00M |
| Investments in Property Plant and Equipment | $-102.00M | $-90.00M | $-64.00M | $-145.00M | $-94.00M | $-80.00M | $-70.00M | $-143.00M | $-77.00M | $-74.00M | $-59.00M | $-100.00M | $-73.00M | $-60.00M | $-55.00M | $-55.00M |
| Acquisitions Net | $-54.00M | $- | $-259.00M | $- | $147.00M | $- | $-20.00M | $-127.00M | $1.00M | $- | $- | $3.00M | $-1.46B | $- | $-13.00M | $-13.00M |
| Purchases of Investments | $-7.00M | $-33.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $-77.00M | $-14.00M | $-27.00M | $-43.00M | $6.00M | $-40.00M | $6.00M | $4.00M | $-19.00M | $-44.00M | $-26.00M | $-3.00M | $-4.00M | $-24.00M | $-4.50M | $-4.50M |
| Net Cash Used for Investing Activities | $-240.00M | $-137.00M | $-349.00M | $-188.00M | $-88.00M | $-120.00M | $-84.00M | $-266.00M | $-95.00M | $-118.00M | $-85.00M | $-100.00M | $-1.53B | $-84.00M | $-72.50M | $-72.50M |
| Debt Repayment | $-1.25B | $987.00M | $-4.00M | $-151.00M | $-860.00M | $17.00M | $-3.00M | $1.99B | $8.20B | $8.00M | $- | $1.00M | $-2.00M | $-2.00M | $- | $- |
| Common Stock Issued | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $-14.00M | $-13.00M | $-14.00M | $-14.00M | $-13.00M | $-14.00M | $-14.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-8.00M | $-60.00M | $-39.00M | $12.00M | $-27.00M | $-27.00M | $-210.00M | $-1.31B | $-8.23B | $-513.00M | $140.00M | $-421.00M | $1.40B | $-583.00M | $-539.50M | $-539.50M |
| Net Cash Used Provided by Financing Activities | $-1.28B | $914.00M | $-57.00M | $-153.00M | $-900.00M | $-24.00M | $-227.00M | $673.00M | $-37.00M | $-505.00M | $140.00M | $-420.00M | $1.40B | $-585.00M | $-539.50M | $-539.50M |
| Effect of Forex Changes on Cash | $-75.00M | $41.00M | $-22.00M | $-19.00M | $24.00M | $-31.00M | $-11.00M | $8.00M | $37.00M | $-25.00M | $-12.00M | $-3.00M | $-11.00M | $-12.00M | $-5.50M | $-5.50M |
| Net Change in Cash | $-679.00M | $1.56B | $-549.00M | $59.00M | $86.00M | $475.00M | $-389.00M | $883.00M | $947.00M | $-26.00M | $24.00M | $-55.00M | $-153.00M | $-103.00M | $-97.50M | $-97.50M |
| Cash at End of Period | $2.89B | $3.57B | $2.01B | $2.56B | $2.51B | $2.42B | $1.95B | $2.33B | $1.45B | $504.00M | $530.00M | $506.00M | $561.00M | $714.00M | $817.00M | $-97.50M |
| Cash at Beginning of Period | $3.57B | $2.01B | $2.56B | $2.51B | $2.42B | $1.95B | $2.33B | $1.45B | $504.00M | $530.00M | $506.00M | $561.00M | $714.00M | $817.00M | $914.50M | $- |
| Operating Cash Flow | $913.00M | $738.00M | $-119.00M | $419.00M | $1.05B | $650.00M | $-67.00M | $468.00M | $1.04B | $622.00M | $-19.00M | $468.00M | $-11.00M | $578.00M | $520.00M | $520.00M |
| Capital Expenditure | $-102.00M | $-90.00M | $-64.00M | $-145.00M | $-94.00M | $-80.00M | $-70.00M | $-143.00M | $-77.00M | $-74.00M | $-59.00M | $-100.00M | $-73.00M | $-60.00M | $-55.00M | $-55.00M |
| Free Cash Flow | $811.00M | $648.00M | $-183.00M | $274.00M | $956.00M | $570.00M | $-137.00M | $325.00M | $965.00M | $548.00M | $-78.00M | $368.00M | $-84.00M | $518.00M | $465.00M | $465.00M |
GE HealthCare Technologies Dividends
Explore GE HealthCare Technologies's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
0.15%
Dividend Payout Ratio
2.76%
Dividend Paid & Capex Coverage Ratio
4.28x
GE HealthCare Technologies Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.035 | $0.035 | January 14, 2025 | January 14, 2025 | February 14, 2025 | November 21, 2024 |
| $0.03 | $0.03 | October 18, 2024 | October 18, 2024 | November 15, 2024 | September 18, 2024 |
| $0.03 | $0.03 | July 19, 2024 | July 19, 2024 | August 15, 2024 | June 26, 2024 |
| $0.03 | $0.03 | April 18, 2024 | April 19, 2024 | May 15, 2024 | March 22, 2024 |
| $0.03 | $0.03 | April 15, 2024 | April 19, 2024 | May 15, 2024 | |
| $0.03 | $0.03 | January 12, 2024 | January 16, 2024 | February 15, 2024 | December 08, 2023 |
| $0.03 | $0.03 | October 19, 2023 | October 20, 2023 | November 15, 2023 | September 22, 2023 |
| $0.03 | $0.03 | July 20, 2023 | July 21, 2023 | August 15, 2023 | June 23, 2023 |
| $0.03 | $0.03 | May 22, 2023 | May 23, 2023 | June 15, 2023 | April 25, 2023 |
GE HealthCare Technologies News
Read the latest news about GE HealthCare Technologies, including recent articles, headlines, and updates.
GE HealthCare launches AI-driven, patient-friendly Invenia ABUS Premium to accelerate scanning and drive early cancer detection in dense breasts
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) announced the launch of Invenia™ Automated Breast Ultrasound (ABUS) Premium, the latest 3D ultrasound offering advanced artificial intelligence (AI) and innovative features to drive faster*, reproducible supplemental screening and streamline exam readings on patients with dense breasts. Approximately 71% of cancers occur in dense breasts.1 According to studies across the U.S. and Europe, 40% of women2 and 70% of Asian women3 have dense brea.
3 Under-the-Radar Value AI Stocks With Market-Beating Potential
These three stocks aren't conventionally seen as artificial intelligence (AI) stocks, yet AI is a critical part of the growth story of HVAC and building controls/software company Johnson Controls (JCI 1.58%), and electrical solutions company nVent Electric (NVT 2.45%). Meanwhile, integrating AI-enabled solutions is the key to long-term growth at GE HealthCare (GEHC 0.26%).
GE HealthCare and NVIDIA reimagine diagnostic imaging with autonomous X-ray and ultrasound solutions
SAN JOSE, Calif.--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced a collaboration with NVIDIA at GTC 2025, expanding the existing relationship between the two companies to focus on pioneering innovation in autonomous imaging, beginning with autonomous X-ray technologies and autonomous applications within ultrasound. GE HealthCare has been at the forefront of medical technology innovation with a series of “firsts” that date back more than a century, starting with the invention of i.
GE HealthCare expands invasive cardiology solutions portfolio with AltiX AI.i for elevated experience in catheterization lab and electrophysiology procedures
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the launch of the AltiX AI.i edition of Mac-Lab™, CardioLab™ and ComboLab™. The AltiX AI.i editions are designed to improve the user experience, elevating workflow in the cardiac catheterization (cath) lab and supporting even the most complex electrophysiology (EP) procedures. These latest editions offer new features that can streamline workflow and enhance interoperability, while upholding strong cybersecurity standards. Ca.
GE HealthCare names new president and CEO, China
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), a leading global healthcare solutions provider, today announced that Yihao Zhang, president and CEO, China, will retire from the company effective July 1, 2025. Will Song, a Johnson & Johnson veteran for over 20 years, has been named GE HealthCare's new president and CEO, China, and will join the company on April 1, 2025, ahead of leading the region starting July 1 following Yihao's departure. Yihao's planned retirement allowed GE Heal.
Enlitic and GE HealthCare to Collaborate to Redefine Imaging Data Migration and Cloud Solutions for Enterprise Imaging
FORT COLLINS, Colo., Feb. 17, 2025 (GLOBE NEWSWIRE) -- Enlitic, Inc., (ASX:ENL) a leader in healthcare imaging data solutions, and its subsidiary Laitek, announces a collaboration with GE HealthCare, a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator.
GE HealthCare Technologies Inc. (GEHC) Q4 2024 Earnings Call Transcript
GE HealthCare Technologies Inc. (NASDAQ:GEHC ) Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ET Company Participants Carolynne Borders - Chief IR Officer Peter Arduini - President and CEO Jay Saccaro - VP and CFO Conference Call Participants Anthony Petrone - Mizuho Financial Group Craig Bijou - BofA Securities Vijay Kumar - Evercore ISI Matt Taylor - Jefferies Joanne Wuensch - Citi Larry Biegelsen - Wells Fargo David Roman - Goldman Sachs Robbie Marcus - JPMorgan Operator Good day, and thank you for standing by. Welcome to the GE HealthCare Fourth Quarter and Full Year 2024 Earnings Conference Call.
GE HealthCare Tops Q4 EPS Forecasts
Medical technology and pharmaceutical diagnostics specialist GE HealthCare Technologies (GEHC -1.30%) reported mixed financial results for the fourth quarter of 2024 on Thursday, Feb. 13. Adjusted earnings per share (EPS) of $1.45 were a significant beat over the anticipated $1.27.
GE HealthCare reports fourth quarter and full year 2024 financial results
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today reported financial results for the fourth quarter and full year ended December 31, 2024. GE HealthCare President and CEO Peter Arduini said, “We were pleased with the strong momentum in orders, backlog and book-to-bill that we saw in the fourth quarter. We also continued to deliver revenue growth driven by demand in our Advanced Visualization Solutions and Pharmaceutical Diagnostics businesses, with overall strength in the U.S., and r.
What Analyst Projections for Key Metrics Reveal About GE HealthCare (GEHC) Q4 Earnings
Get a deeper insight into the potential performance of GE HealthCare (GEHC) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for GEHC.